Request Demo

Last update 08 May 2025

Polychondritis, Relapsing

Last update 08 May 2025

Basic Info

Synonyms

Atrophic Polychondritides, Chronic, Atrophic Polychondritis, Chronic, CHONDROMALACIA, SYSTEMIC

+ [52]

Introduction

An acquired disease of unknown etiology, chronic course, and tendency to recur. It is characterized by inflammation and degeneration of cartilage and can result in deformities such as floppy ear and saddle nose. Loss of cartilage in the respiratory tract can lead to respiratory obstruction.

Drugs associated with Polychondritis, Relapsing

Abatacept

Target

CD80 x CD86

Mechanism

CD80 modulators [+1]

Active Org.

Bristol Myers Squibb Co. [+4]

Originator Org.

Bristol Myers Squibb Co.

Active Indication

Acute Graft Versus Host Disease [+19]

Inactive Indication

airway disease [+39]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date23 Dec 2005

Prednisone

Target

Mechanism

GR antagonists

Active Org.

Janssen Research & Development LLC [+7]

Originator Org.

Merck Sharp & Dohme Corp.

Active Indication

Autoimmune Diseases [+11]

Inactive Indication

acute leukemia [+69]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date21 Feb 1955

Clinical Trials associated with Polychondritis, Relapsing

NCT06941376

/ Not yet recruitingPhase 2IIT

Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).

Start Date01 Jul 2025

Sponsor / Collaborator

University of Pennsylvania

NCT06873100

/ RecruitingPhase 1/2IIT

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures.
The goal of this clinical trial is to learn if drug Upadacitinib works to treat relapsing polychondritis in adults. It will also learn about the safety of drug Upadacitinib. The main questions it aims to answer are:
* Does drug Upadacitinib reduce the disease activity of relapsing polychondritis?
* What medical problems do participants have when taking drug Upadacitinib? Researchers will compare drug Upadacitinib to conventional therapies (treatment with corticosteroids combined with immunosuppressants) to see if drug Upadacitinib works to treat relapsing polychondritis.
Participants will:
* Take drug Upadacitinib or corticosteroids combined with immunosuppressants every day for 24 weeks.
* Visit the hospital once every month for checkups and tests. This clinical study will explore the efficacy and immunological evaluation of Upadacitinib in the treatment of RP.

Start Date15 Nov 2024

Sponsor / Collaborator

Peking University People's Hospital

NCT06561568

/ Active, not recruitingNot ApplicableIIT

Additional Effects of Kinesio Taping on Knee Joint Proprioception and Spatiotemporal Gait Parameters in Patient With Chrondromalacia Patellae

Chondromalacia patellae (CMP), also known as runner's knee, is characterized by anterior knee pain (AKP) and typically occurs in youngsters. Causes of chondromalacia patellae include micro trauma wear and tear, post traumatic injuries and muscular imbalance. In Chondromalacia patella pain is behind or around the patella caused by stress in the patellofemoral joint that usually provoked by climbing stairs, squatting, and sitting with flexed knees for longer time periods. Patients of CMP presents with patellar mal-tracking, muscular weakness, proprioceptive deficit. Exercise training has been proven beneficial for CMP patients but additive effect of kinesio taping along with exercise have not been seen yet in these patients. The study will help people with chondromalacia patellae to improve their quality of life. The findings will contribute to future research in chondromalacia patellae management.

Start Date10 Jun 2024

Sponsor / Collaborator

Foundation University Islamabad

100 Clinical Results associated with Polychondritis, Relapsing

100 Translational Medicine associated with Polychondritis, Relapsing

0 Patents (Medical) associated with Polychondritis, Relapsing

1,737

Literatures (Medical) associated with Polychondritis, Relapsing

24 Mar 2025·Cureus

Early Diagnosis of Relapsing Polychondritis With Airway Involvement: A Case Report

Article

Author: Shundo, Yuki ; Himuro, Naoko ; Hamada, Naoki ; Fujita, Masaki ; Kushima, Natsumi ; Yanagihara, Toyoshi

Relapsing polychondritis (RP) is a rare systemic immune-mediated disease that causes recurrent inflammation of cartilaginous tissues. Airway involvement is a significant prognostic factor; however, diagnosis is often delayed because of nonspecific symptoms. We report the case of a 38-year-old woman who presented with pharyngeal discomfort, cough, and chest pain. Initial tests revealed elevated inflammatory markers and anemia. A chest CT scan showed soft tissue enhancement around the costal cartilage and thickening of the tracheal and bronchial walls. Bronchoscopy demonstrated extensive inflammation from the larynx to the main bronchi, with approximately 90% narrowing of the left bronchus during exhalation, suggestive of tracheomalacia. Based on clinical findings, imaging, bronchoscopy, and serological tests, a diagnosis of RP was made, fulfilling McAdam's and Damiani's criteria. Although pulmonary function tests continued to show obstructive ventilatory impairment, treatment withcorticosteroids (0.6 mg/kg prednisolone) and methotrexate resulted in rapid improvement in inflammatory markers and imaging findings. This case highlights the importance of early bronchoscopy in assessing airway involvement in RP, even when respiratory symptoms are mild, and emphasizes the need to balance the diagnostic benefits against potential risks, particularly in those with reduced forced vital capacity. Early diagnosis and timely intervention, including consideration of biologics, may prevent progression to severe airway compromise.

01 Mar 2025·La Revue de Médecine Interne

Syndromes auto-inflammatoires VEXAS-like : à propos de 2 cas

Article

Author: Masson, Helene ; Hirsch, Pierre ; Chretiennot, Andrea ; Mekinian, Arsene ; Devaux, Mathilde ; Jachiet, Vincent ; Salmeron, Geraldine ; Georgin-Lavialle, Sophie ; Sep-Hieng, Sonnthida ; Le Lostec, Zoe ; Veyssier-Belot, Catherine ; Ghit, Lilia ; Flandrin-Gresta, Pascale

INTRODUCTIONVEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), recently described, due to a somatic mutation of the UBA1 gene and often associated with hemopathy, is characterized by systemic symptoms close to those described in Still's disease or relapsing polychondritis. There are also patients with hemopathy, presenting inflammatory symptoms reminiscent of those of VEXAS syndrome but without mutation of the UBA1 gene.CASE/DISCUSSIONTwo male patients consulted for general signs, dermatological symptoms, arthralgia, chondritis and venous thrombosis, like patients in the French cohort suffering from VEXAS syndrome. The myelogram found vacuoles in the myeloid and erythroid precursors, with a diagnosis of chronic myelomonocytic leukemia for one and myelodysplastic syndrome for the other. The search for a mutation of the UBA1 gene by the sanger technique, the next-generation sequencing (NGS) analysis of a myeloid panel and the complete sequencing was negative, not allowing the diagnosis of VEXAS syndrome to be retained. There were other somatic mutations, indicating clonal hematopoiesis associated with this systemic inflammatory state. Initial corticosteroid therapy was effective but corticosteroid dependence required sparing treatment with hypomethylating agents or Janus Kinase inhibitors.CONCLUSIONThe role of somatic mutations in the pathophysiology of autoinflammatory diseases associated with hematologic diseases must be better understood in order to better characterize them and develop targeted treatments.

16 Feb 2025·Cureus

Sclerokeratitis and Secondary Glaucoma in Relapsing Polychondritis in a 30-Year-Old Asian Male Patient: A Case Report

Article

Author: Flores, Lovely Keziah C ; Siazon, Richmond R

Relapsing polychondritis (RPC) is an immune-mediated systemic disease characterized by recurring inflammatory episodes in cartilage structures, mainly in the ears, nose, and respiratory tract. It is associated with various systemic and ocular manifestations, such as scleritis, the most common ocular feature of RPC. Scleromalacia perforans (SP) is a rare and severe form of anterior scleritis that appears as a dark bluish discoloration and bulging of a thinned-out sclera in the absence of pain or redness. This case report describes a 30-year-old Asian male who presented a seven-year history of blurred vision and recurrent eye redness. Visual acuity (VA) was 15/200 and 20/63+2 on OD and OS, respectively. An eye exam showed diffusely hazy cornea, thinned-out sclera, and elevated intraocular pressure (IOP) in both eyes. A systems review revealed bilateral auriculitis and mixed hearing loss. He was clinically diagnosed with RP and started on systemic corticosteroids at 1 mg/kg/day. On follow-up, the patient showed resolution of conjunctival hyperemia; however, IOP remains elevated despite maximal therapy. Ocular manifestations in RPC are protean and may be the presenting symptoms of RPC, resulting in the possibility of delayed or missed diagnosis in the absence of chondritis. SP, corneal scarring, and secondary glaucoma are late sequelae and vision-threatening conditions that may pose significant therapeutic challenges to ophthalmologists. Multispecialty collaboration is warranted in the management of systemic complications of RPC.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Polychondritis, Relapsing

Basic Info

Related

Analysis